Stifel downgraded Alector (ALEC) to Hold from Buy with a $4 price target The failure of Alector’s TREM2 asset, AL002, in a Phase 2 Alzheimer’s study was “a major setback” and the stock is down about 70% year-to-date, the analyst tells investors. Examining the key questions heading into 2025 – namely if latozinemab has a “credible shot” in the FTD-GRN Phase 3 due late-2025/early-2026 and how “real” is their early-stage BBB platform – the analyst contends that “both are challenging to have true conviction in.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- GE Vernova initiated, Merck upgraded: Wall Street’s top analyst calls
- Alector downgraded to Underperform at BofA after Alzheimer’s trial miss
- Alector downgraded to Underperform from Neutral at BofA
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Alector shares may settle in $2.50-$3.50 range, says Mizuho
Questions or Comments about the article? Write to editor@tipranks.com